Veeva Vault CTMS Launched at Bristol Myers Squibb to Simplify Clinical Trial Processes Globally

Veeva Systems today announced that Bristol Myers Squibb has implemented Veeva Vault CTMS (Clinical Trial Management System) globally to drive end-to-end trial management. The new CTMS replaced a heritage Celgene CTMS and a heritage Bristol Myers Squibb CTMS and is tightly integrated with Veeva's eTMF and Study Startup applications. The total implementation time was less than 20 months.

By launching Veeva's industry-leading trial management and monitoring solution companywide, Bristol Myers Squibb established unified, agile, and simple trial processes aimed at making clinical trials faster and more efficient.

"We're thrilled to expand on our longstanding partnership with Veeva across R&D," said Greg Meyers, chief digital and technology officer at Bristol Myers Squibb. "Veeva's continued commitment to customer success and product innovation helps us accelerate the development and delivery of medicines to patients globally."

"Bristol Myers Squibb is one of our most agile and forward-thinking partners," said Veeva CEO Peter Gassner. "The merger of Bristol Myers Squibb and Celgene was the largest IT integration project in the history of pharma and to have completed a single CTMS implementation in twenty months is truly remarkable. We are very proud to achieve this milestone together."